Analysis of the search for COVID-19 vaccines in South American countries

Authors

Keywords:

vaccines, pandemic, coronavirus infections, Latin America.

Abstract

Introduction: Since the development of COVID-19 vaccines, the world population has been increasingly interested in learning about them.
Objective: To perform a search analysis on COVID-19 vaccines in South American countries.
Methods: Observational, descriptive, and retrospective study; of data obtained from the Google Trends tool. The use of 6 terms ("COVID-19 vaccine", "Effectiveness of COVID-19 vaccines", "Pfizer vaccine", "Sinopharm vaccine", "side effects of Pfizer vaccine", "side effects of Sinopharm vaccine") was compared in nine Spanish-speaking South American countries.
Results: The country with the highest search result for the term "COVID-19 vaccine" was Bolivia. Regarding the search for the term "COVID vaccine effectiveness" in South American countries, there is a strong trend in Peru, Ecuador, Argentina and Chile, between January and July 2021.
Conclusion: There was no decrease in the general interest regarding the 6 terms used for this study; however, the general interest in coronavirus vaccines among Google search engine users has presented changes in the trend, while the popularity of COVID-19 vaccine side effects has increased, showing significant variation according to the context of each country.

Downloads

Download data is not yet available.

References

1. OPS/OMS. La OMS caracteriza a COVID-19 como una pandemia. Organización Panamericana de la Salud. 2020 [acceso 25/12/2021]. Disponible en: https://www.paho.org/es/noticias/11-3-2020-oms-caracteriza-covid-19-como-pandemia

2. Arshad Ali S, Baloch M, Ahmed N, Arshad Ali A, Iqbal A. The outbreak of Coronavirus Disease 2019 (COVID-19)-An emerging global health threat. J Infect Public Health. 2020; 13(4):644-6. DOI: 10.1016/j.jiph.2020.02.033

3. Cabezas C. Pandemia de la COVID-19: tormentas y retos. Rev Peru Med Exp Salud Pública. 2021; 37(4):603-4. DOI: 10.17843/rpmesp.2020.374.6866

4. Tregoning JS, Flight KE, Higham SL, Wang Z, Pierce BF. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat Rev Immunol. 2021; 21(10):626-36. DOI: 10.1038/s41577-021-00592-1

5. Mathieu E, Ritchie H, Ortiz-Ospina E, Roser M, Hasell J, Appel C, et al. A global database of COVID-19 vaccinations. Nat Hum Behav. 2021; 5(7):947-53. DOI: 10.1038/s41562-021-01122-8

6. Kaewkitipong L, Chen C, Ractham P. Examining factors influencing COVID-19 vaccine tourism for international tourists. Sustainability. 2021; 13(22):12867. DOI: 10.3390/su132212867

7. Redaccion A21. Disminuye turismo mexicano de vacunas. Mexico. 2021 [acceso: 25/12/2021]. Disponible en: http://a21.com.mx/index.php/aeronautica/2021/08/04/disminuye-turismo-mexicano-de-vacunas

8. Raza F, Lantos JD. Promoting COVID-19 vaccination on social media. Pediatrics. 2021; 147(5):e2021050049. DOI: 10.1542/peds.2021-050049

9. Nuti SV, Wayda B, Ranasinghe I, Wang S, Dreyer RP, Chen SI, et al. The use of google trends in health care research: a systematic review. PloSOne. 2014; 9(10):e109583. DOI: 10.1371/journal.pone.0109583

10. Meo SA, Bukhari IA, Akram J, Meo AS, Klonoff DC. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. Eur Rev Med Pharmacol Sci. 2021; 25(3):1663-9. DOI: 10.26355/eurrev_202102_24877

11. Saeed BQ, Al-Shahrabi R, Alhaj SS, Alkokhardi ZM, Adrees AO. Side effects and perceptions following Sinopharm COVID-19 vaccination. Int J Infect Dis. 2021; 111(1):219-26. DOI: 10.1016/j.ijid.2021.08.013

12. COVID Live. Coronavirus Statistics. Worldometer. 2021 [acceso: 25/12/2021]. Disponible en: https://www.worldometers.info/coronavirus/#countries

13. BBC. Perú duplica las muertes por covid-19 tras una revisión de cifras y se convierte en el país con la mayor tasa de mortalidad per cápita del mundo. BBC News Mundo. 2021 [acceso: 25/12/2021]. Disponible en: https://www.bbc.com/mundo/noticias-america-latina-57310960

14. OPS/OMS. Bolivia recibe las primeras 228 mil dosis de vacunas COVID-19 a través del Mecanismo COVAX. Organización Panamericana de la Salud. 2021 [acceso: 25/12/2021]. Disponible en: https://www.paho.org/es/noticias/21-3-2021-bolivia-recibe-primeras-228-mil-dosis-vacunas-covid-19-traves-mecanismo-covax

15. Carranza Jimenez DC. Llegan a Uruguay las primeras 192 mil vacunas contra la COVID-19 de Sinovac. Agencia Anadolau. 2021 [acceso: 25/12/2021]. Disponible en: https://www.aa.com.tr/es/mundo/llegan-a-uruguay-las-primeras-192-mil-vacunas-contra-la-covid-19-de-sinovac/2158281

16. Agencia EFE S.A. Uruguay recibirá las primeras 50.000 vacunas de Pfizer el 10 de marzo. SWI swissinfo.ch. 2021 [acceso: 25/12/2021]. Disponible en: https://www.swissinfo.ch/spa/coronavirus-uruguay_uruguay-recibir%C3%A1-las-primeras-50.000-vacunas-de-pfizer-el-10-de-marzo/46418972

17. Burki T. The online anti-vaccine movement in the age of COVID-19. Lancet Digit Health. 2020; 2(10):e504-5. DOI: 10.1016/S2589-7500(20)30227-2

18. Chagla Z. The BNT162b2 (BioNTech/Pfizer) vaccine had 95% efficacy against COVID-19 ≥7 days after the 2nd dose. Ann Intern Med. 2021; 174(2):JC15. DOI: 10.7326/ACPJ202102160-015

19. Redacción Gestión. Primer lote de vacunas de Sinopharm llegará al Perú el 9 de febrero. Gestion noticias. 2021 [acceso: 25/12/2021]. Disponible en: https://gestion.pe/peru/primer-lote-de-vacunas-de-sinopharm-llegara-al-peru-el-9-de-febrero-coronavirus-peru-nndc-noticia/

20. MINSA - DIGEMID. Eventos adversos supuestamente atribuidos a la vacunación o Inmunización (ESAVI) reportados a la vacuna contra la COVID-19, periodo del 09 de febrero al 31 de julio de 2021. Perú: Ministerio de salud, Dirección General de Medicamentos, Insumos y Drogas; 2021. [acceso: 25/12/2021]. Disponible en: http://repositorio.digemid.minsa.gob.pe/xmlui/handle/DIGEMID/214

21. Wong LP, Alias H, Danaee M, Ahmed J, Lachyan A, Cai CZ, et al. COVID-19 vaccination intention and vaccine characteristics influencing vaccination acceptance: a global survey of 17 countries. Infect Dis Poverty. 2021; 10(1):122. DOI: 10.1186/s40249-021-00900-w

22. Meyer MN, Gjorgjieva T, Rosica D. Trends in health care worker intentions to receive a COVID-19 vaccine and reasons for hesitancy. JAMA Netw Open. 2021; 4(3):e215344. DOI: 10.1001/jamanetworkopen.2021.5344

23. Kaplan RM, Milstein A. Influence of a COVID-19 vaccine's effectiveness and safety profile on vaccination acceptance. Proc Natl Acad Sci. 2021; 118(10):1-5. DOI: 10.1073/pnas.2021726118

24. Coustasse A, Kimble C, Maxik K. COVID-19 and vaccine hesitancy: A challenge the United States must overcome. J Ambulatory Care Manage. 2021; 44(1):71-5. DOI: 10.1097/JAC.0000000000000360

Downloads

Published

2022-12-15

How to Cite

1.
Santos-Rosales YR, Aliaga-Cáceres BS, Tovar-Yaro EJ, Bernuy-Portilla M, Huanca-Mamani VI, Armada J, et al. Analysis of the search for COVID-19 vaccines in South American countries. Rev Cubana Med Milit [Internet]. 2022 Dec. 15 [cited 2025 May 9];51(4):e02202067. Available from: https://revmedmilitar.sld.cu/index.php/mil/article/view/2067

Issue

Vol. 51 No. 4 (2022): October - December

Section

Research Article

License

Authors who have publications with this Journal accept the following terms:

  • The authors will retain their copyright and guarantee the Journal the right of first publication of their work, which will simultaneously be subject to the Creative Commons Attribution License. The content presented here can be shared, copied and redistributed in any medium or format; Can be adapted, remixed, transformed or created from the material, using the following terms: Attribution (giving appropriate credit to the work, providing a link to the license, and indicating if changes have been made); non-commercial (you cannot use the material for commercial purposes) and share-alike (if you remix, transform or create new material from this work, you can distribute your contribution as long as you use the same license as the original work).
  • The authors may adopt other non-exclusive license agreements for the distribution of the published version of the work (for example: depositing it in an institutional electronic archive or publishing it in a monographic volume) as long as the initial publication in this Journal is indicated.
  • Authors are allowed and recommended to disseminate their work through the Internet (e.g., in institutional electronic archives or on their website) before and during the submission process, which can produce interesting exchanges and increase citations. of the published work.